Pharmaceutical Executive, Jul 1, 2010 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jul 1, 2010
Features
Managing the Middle
By Nancy Lurker
Outsourcing the sales representative function can help pharmaceutical companies build on their bottom line.
Road Map for REMS
By Thani Jambulingam, St. Josephs University
FDA's risk-reduction requirements could be the bridge to a bright new future for the pharma industry.
Media Spend Trends
By Oriana Schwindt
Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?
Columns
Adherence: Missing the Mark
By Andrea LaFountain
Why do patients drop drug therapy after 12 months?
In Defense of the Battered Sales Rep
By Scott Moldenhauer
Why pharma sales representatives are still the best marketers and how to make them better.
Augmented Reality: The New, New Media
By Guy Mastrion
New strategies like augmented reality can increase patient compliance and knowledge.
Washington Report
Tackling Transparency
By Jill Wechsler
Drug prices, doctor payments, and FDA regulatory decisions are candidates for expanded disclosure.
Global
Emerging Markets Under Anti-Corruption Microscope
By L. Stephen Vincze
As they build market share, companies need a plan to limit exposure to steep fines and executive prosecutions.
Leadership
Splitting Image
By Clifford Kalb
Once occupied by a single pharma leader, the roles of CEO, president, and board chairman are increasingly being separated. What's behind the trend?
Competition
Big Pharma's Most Feared Competitor
By Stan Bernard, MD
Teva Pharmaceuticals has emerged as the industry's most formidable foe.
From the Editor
BP and Big Pharma: A Warning Sign
By William Looney
If there was ever a justification for endorsing a "triple bottom line" strategy for measuring Big Pharma's investment performance, it's the BP crisis.

ADVERTISEMENT

Click here